Targeting CD19 CAR-T With MND Promoter Enhances Tumour Killing.

Although Chimeric antigen receptor (CAR) T cell therapy has demonstrated a high remission rate in B cell acute lymphoblastic leukaemia, concerns regarding toxicity and disease recurrence remain. Different promoters can modulate the expression levels of CAR molecules on the cell surface. In this study, we systematically compared four distinct promoters (MND, MSCV, EF-1α and CMV). Our findings revealed that while these promoters exhibited similar characteristics, the MND promoter demonstrated superior viral packaging and transduction efficiency. Furthermore, it enhanced the anti-leukaemia efficacy by increasing the proportion of naïve T cells involved in the cytotoxic process.